糖尿病及其管理方式与降主动脉瘤腔内修复术后结局的关联
基于血管质量倡议(VQI)2014至2022年因降主动脉瘤行胸主动脉腔内修复(TEVAR)的2637例患者,其中473例(18%)术前存在糖尿病。多变量分析显示糖尿病与围术期及5年死亡风险相似,但饮食管理的糖尿病与更高的围术期死亡(OR 2.16)和5年死亡(HR 1.50)相关。
要点
- 糖尿病患者TEVAR后围术期死亡(OR 1.14)与5年死亡(HR 1.15)与非糖尿病患者相似。
- 饮食管理的糖尿病与更高的围术期死亡(OR 2.16)和5年死亡(HR 1.50)相关。
- 无糖尿病者1年瘤囊回缩47% vs 糖尿病者46%(P = .27),各组瘤囊动态相似。
核心结论
- 因降主动脉瘤行TEVAR的患者中,糖尿病与围术期及5年死亡风险相似,但饮食治疗的糖尿病与显著更高的围术期死亡和5年死亡相关。
研究设计与样本
- 基于血管质量倡议(VQI)2014至2022年因降主动脉瘤行TEVAR的患者,按术前糖尿病状态分为糖尿病组与非糖尿病组,并将糖尿病组按管理策略分为饮食管理、非胰岛素药物和胰岛素治疗亚组。
- 共识别2637例患者,其中473例(18%)术前存在糖尿病;糖尿病患者中25%为饮食控制、54%为非胰岛素药物、21%为胰岛素治疗。
- 结局包括围术期和5年死亡、院内并发症、修复指征及1年瘤囊动态,分别采用多变量Cox回归、多变量logistic回归和χ2检验分析。
主要发现
- 因胸主动脉瘤行TEVAR的患者中,破裂表现比例在饮食管理组(11.1%)和胰岛素管理组(14.3%)高于非胰岛素治疗组(6.6%)和无糖尿病组(6.9%)。
- 糖尿病与非糖尿病相比,围术期死亡(OR 1.14;95%CI 0.70-1.81)和5年死亡(HR 1.15;95%CI 0.91-1.48)相似,所有院内并发症在两组间相当。
- 与非糖尿病患者相比,饮食管理的糖尿病与更高的调整后围术期死亡(OR 2.16;95%CI 1.03-4.19)和更高的5年死亡(HR 1.50;95%CI 1.03-2.20)显著相关,其他糖尿病亚组未见此关联。
- 1年瘤囊动态在各组相似,瘤囊回缩发生于无糖尿病患者的47% vs 糖尿病患者的46%(P = .27)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Prior literature is conflicted regarding the effect of diabetes mellitus (DM) on outcomes after endovascular repair of aortic aneurysms. In this study, we aimed to examine the association between DM and outcomes after thoracic endovascular aneurysm repair (TEVAR) for thoracic aortic aneurysm (TAA). METHODS: We identified patients who underwent TEVAR for TAA of the descending thoracic aorta in the Vascular Quality Initiative between 2014 and 2022. We created two cohorts, DM and nonDM, based on the patient's preoperative DM status, and secondarily substratified patients with DM by management strategy: dietary management, noninsulin medications, and insulin therapy cohorts. Outcomes included perioperative and 5-year mortality, in-hospital complications, indications for repair, and 1-year sac dynamics, which were analyzed with multivariable cox regression, multivariable logistic regression, and χ2 tests, respectively. RESULTS: We identified 2637 patients, of which 473 (18%) had DM preoperatively. Among patients with DM, 25% were diet controlled, 54% noninsulin medications, and 21% insulin therapy. Within patients who underwent TEVAR for TAA, the proportions of ruptured presentation were higher in the dietary-managed (11.1%) and insulin-managed (14.3%) cohorts relative to noninsulin therapy (6.6%) and those without DM (6.9%). After multivariable regression analysis, we found that DM was associated with similar perioperative mortality (odds ratio, 1.14; 95% confidence interval [CI], 0.70-1.81) and 5-year mortality compared with patients without DM (hazard ratio, 1.15; 95% CI, 0.91-1.48). Furthermore, all in-hospital complications were comparable between patients with DM and patients without DM. Compared with patients without DM, dietary management of DM was significantly associated with higher adjusted perioperative mortality (OR, 2.16; 95% CI, 1.03-4.19) and higher 5-year mortality (hazad ratio, 1.50; 95% CI, 1.03-2.20), although this was not the case for other DM subgroups. All cohorts displayed similar 1-year sac dynamics, with sac regression occurring in 47% of patients without DM vs 46% of patients with DM (P = .27). CONCLUSIONS: Preoperatively, patients with DM who underwent TEVAR had a higher proportion of ruptured presentation when treated with diet or insulin medications than when treated with noninsulin medications. After TEVAR for descending TAA, DM was associated with a similar risk of perioperative and 5-year mortality as nonDM. In contrast, dietary therapy for DM was associated with significantly higher perioperative mortality and 5-year mortality.
引用
- Summers SP, Rastogi V, Yadavalli SD, et al. The association between diabetes mellitus and its management with outcomes following endovascular repair for descending thoracic aortic aneurysm. J Vasc Surg. 2023. PMID: 36966848. doi:10.1016/j.jvs.2023.02.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。